Back to Search
Start Over
Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study.
- Source :
- Oncologist; Aug2010, Vol. 15 Issue 8, p799-809, 11p, 1 Diagram, 3 Charts, 3 Graphs
- Publication Year :
- 2010
-
Abstract
- Background. The Hermine study observed the use of trastuzumab for metastatic breast cancer (MBC) in routine practice, including patients who received trastuzumab treatment beyond progression (TBP). Patients and Methods. The study observed 623 patients for ≥2 years. Treatment was given according to oncologists' normal clinical practices. Endpoints included duration of treatment, efficacy, and cardiac safety. The TBP subanalysis compared overall survival (OS) in 177 patients who received first-line trastuzumab and either continued trastuzumab for ≥30 days following progression or stopped at or before progression. Results. The median treatment duration was 13.3 months. In the first-, second-, and third-line or beyond treatment groups, the median time to progression (TTP) were 10.3 months, 9.0 months, and 6.3 months, and the median OS times were 30.3 months, 27.1 months, and 23.2 months, respectively. Heart failure was observed in 2.6% of patients, although no cardiac-associated deaths occurred. In the TBP subanalysis, the median OS duration from treatment initiation and time of disease progression were longer in patients who continued receiving trastuzumab TBP (>27.8 months and 21.3 months, respectively) than in those who stopped (16.8 months and 4.6 months, respectively). However, the groups were not completely comparable, because patients who continued trastuzumab TBP had better prognoses at treatment initiation. The median TTP was longer in patients who continued trastuzumab TBP (10.2 months) than in those who stopped (7.1 months). Conclusion. The Hermine findings confirm that the pivotal trials of first-line trastuzumab treatment in MBC patients are applicable in clinical practice. The subanalysis suggests that trastuzumab TBP offers a survival benefit to MBC patients treated with first-line trastuzumab. [ABSTRACT FROM AUTHOR]
- Subjects :
- BREAST tumors
COMPUTER software
CONFIDENCE intervals
LONGITUDINAL method
MEDICAL cooperation
METASTASIS
SCIENTIFIC observation
ONCOGENES
REGRESSION analysis
RESEARCH
SURVIVAL analysis (Biometry)
DECISION making in clinical medicine
TRASTUZUMAB
DATA analysis
PREDICTIVE tests
RETROSPECTIVE studies
DISEASE progression
TREATMENT duration
DRUG administration
DRUG dosage
DRUG therapy
Subjects
Details
- Language :
- English
- ISSN :
- 10837159
- Volume :
- 15
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Oncologist
- Publication Type :
- Academic Journal
- Accession number :
- 55533660
- Full Text :
- https://doi.org/10.1634/theoncologist.2009-0029